Tick-borne encephalitis vaccine
FSME-Immun (European TBE vaccine) | |
| Vaccine description | |
|---|---|
| Target | Tick-borne encephalitis virus |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Encepur N, FSME-Immun CC, Ticovac, others |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| KEGG | |
| (what is this?) (verify) | |
Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE). The disease is most common in Central and Eastern Europe, and Northern Asia. More than 87% of people who receive the vaccine develop immunity. It is not useful following the bite of an infected tick. It is given by injection into a muscle.
The World Health Organization (WHO) recommends immunizing all people in areas where the disease is common. Otherwise the vaccine is just recommended for those who are at high risk. Three doses are recommended followed by additional doses every three to five years. The vaccines can be used in people more than one or three years of age depending on the formulation. The vaccine appears to be safe during pregnancy.
Serious side effects are very uncommon. Minor side effects may include fever, and redness and pain at the site of injection. Older formulations were more commonly associated with side effects.
The first vaccine against TBE was developed in 1937. It is on the World Health Organization's List of Essential Medicines. The vaccine was approved for medical use in the United States in August 2021.